Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

797 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ischemic stroke in patients with primary brain tumors.
Kreisl TN, Toothaker T, Karimi S, DeAngelis LM. Kreisl TN, et al. Among authors: karimi s. Neurology. 2008 Jun 10;70(24):2314-20. doi: 10.1212/01.wnl.0000314648.82924.6f. Neurology. 2008. PMID: 18541885
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE. Clarke JL, et al. Among authors: karimi s. J Clin Oncol. 2009 Aug 10;27(23):3861-7. doi: 10.1200/JCO.2008.20.7944. Epub 2009 Jun 8. J Clin Oncol. 2009. PMID: 19506159 Free PMC article. Clinical Trial.
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas.
Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, Holland EC, Hormigo A. Iwamoto FM, et al. Among authors: karimi s. J Neurooncol. 2011 Dec;105(3):607-12. doi: 10.1007/s11060-011-0628-z. Epub 2011 Jun 28. J Neurooncol. 2011. PMID: 21710351 Free PMC article.
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A. Iwamoto FM, et al. Among authors: karimi s. Neuro Oncol. 2011 Nov;13(11):1244-51. doi: 10.1093/neuonc/nor117. Epub 2011 Aug 10. Neuro Oncol. 2011. PMID: 21831900 Free PMC article.
Post-treatment T1 shortening in primary CNS lymphoma.
Karimi S, Hatzoglou V, Punia V, Partovi S, Abrey LE, Deangelis LM. Karimi S, et al. J Neurooncol. 2013 Jan;111(1):25-31. doi: 10.1007/s11060-012-0984-3. Epub 2012 Oct 17. J Neurooncol. 2013. PMID: 23073601
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Morris PG, et al. Among authors: karimi s. J Clin Oncol. 2013 Nov 1;31(31):3971-9. doi: 10.1200/JCO.2013.50.4910. Epub 2013 Oct 7. J Clin Oncol. 2013. PMID: 24101038 Free PMC article. Clinical Trial.
APOE polymorphisms and cognitive functions in patients with brain tumors.
Correa DD, Satagopan J, Baser RE, Cheung K, Richards E, Lin M, Karimi S, Lyo J, DeAngelis LM, Orlow I. Correa DD, et al. Among authors: karimi s. Neurology. 2014 Jul 22;83(4):320-7. doi: 10.1212/WNL.0000000000000617. Epub 2014 Jun 18. Neurology. 2014. PMID: 24944262 Free PMC article.
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Kaley TJ, et al. Among authors: karimi s. Neuro Oncol. 2015 Jan;17(1):116-21. doi: 10.1093/neuonc/nou148. Epub 2014 Aug 6. Neuro Oncol. 2015. PMID: 25100872 Free PMC article. Clinical Trial.
797 results